Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2022 16:30 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
July 11, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
June 13, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the JMP Securities Life Sciences Conference

BOSTON, June 13, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
June 01, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
May 26, 2022 17:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
May 11, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers

Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancersStarting dose of 1 mg/kg expected to reduce time and cost...
May 10, 2022 16:30 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2022 Financial Results

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
March 10, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Upcoming Oppenheimer 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively...
March 02, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present an Updated Overview of Immuno-STAT Platform at the 2022 Festival of Biologics World Immunotherapy Congress

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to...
February 15, 2022 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the Biophysical Society 2022 Annual Meeting

Presentation provides mechanistic insights and progress update on collaboration with the laboratory of Michael Dustin at the University of Oxford to study the role of IL-2 in the T cell immunological...